Non- Hodgkin Lymphoma - Pipeline Review, H2 2012

Non- Hodgkin Lymphoma - Pipeline Review, H2 2012

Aug 2012 Global Markets Direct Lymphoma329 Pages Price :
$ 2500

Non-Hodgkin Lymphoma Pipeline Review, H2 2012

Global Markets Directs, \'Non-Hodgkin Lymphoma Pipeline Review, H2 2012\', provides an overview of the Non-Hodgkin Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Non-Hodgkin Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma. \'Non-Hodgkin Lymphoma Pipeline Review, H2 2012\' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Non-Hodgkin Lymphoma.
  • A review of the Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Non-Hodgkin Lymphoma pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Non-Hodgkin Lymphoma therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Non-Hodgkin Lymphoma Therapeutic Products under Development, Key Players in Non-Hodgkin Lymphoma Therapeutics, Non-Hodgkin Lymphoma Pipeline Overview, Non-Hodgkin Lymphoma Pipeline, Non-Hodgkin Lymphoma Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Non-Hodgkin Lymphoma Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Non-Hodgkin Lymphoma 13
Non-Hodgkin Lymphoma Therapeutics under Development by Companies 15
Non-Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes 22
Late Stage Products 32
Comparative Analysis 32
Mid Clinical Stage Products 33
Comparative Analysis 33
Early Clinical Stage Products 34
Comparative Analysis 34
Discovery and Pre-Clinical Stage Products 35
Comparative Analysis 35
Non-Hodgkin Lymphoma Therapeutics Products under Development by Companies 36
Non-Hodgkin Lymphoma Therapeutics Products under Investigation by Universities/Institutes 45
Companies Involved in Non-Hodgkin Lymphoma Therapeutics Development 67
Bristol-Myers Squibb Company 67
Johnson & Johnson 68
Boehringer Ingelheim GmbH 69
F. Hoffmann-La Roche Ltd. 70
Kyowa Hakko Kirin Co., Ltd. 71
Abbott Laboratories 72
Amgen Inc. 73
Sanofi-Aventis 74
Eli Lilly and Company 75
Seattle Genetics, Inc. 76
Genentech, Inc. 77
Antigenics, Inc. 78
Biotec Pharmacon ASA 79
Gilead Sciences, Inc. 80
Merck & Co., Inc. 81
Emergent BioSolutions Inc. 82
Gamida Cell Ltd. 83
Celltrion, Inc. 84
ZIOPHARM Oncology, Inc. 85
Millennium Pharmaceuticals, Inc. 86
Novartis AG 87
Astellas Pharma Inc. 88
Cephalon, Inc. 89
Eisai Co., Ltd. 90
Gedeon Richter Plc. 91
Human Genome Sciences, Inc. 92
ImmunoGen, Inc. 93
Ono Pharmaceutical Co., Ltd. 94
Pfizer Inc. 95
Sigma-Tau S.p.A. 96
SuperGen, Inc. 97
Cell Therapeutics, Inc. 98
Alfacell Corporation 99
Celgene Corporation 100
Incyte Corporation 101
Hana Biosciences, Inc. 102
IMMUNOMEDICS, INC 103
Idera Pharmaceuticals, Inc. 104
MethylGene Inc 105
NexMed, Inc. 106
Northwest Biotherapeutics, Inc. 107
Accentia Biopharmaceuticals, Inc. 108
Allos Therapeutics, Inc 109
Cytokinetics, Inc 110
TopoTarget A/S 111
Mundipharma International Limited 112
Pharmacyclics, Inc. 113
MorphoSys AG 114
Takara Bio Inc. 115
Sareum Holdings plc 116
Innate Pharma SA 117
Transgene Biotek Ltd 118
Spectrum Pharmaceuticals, Inc. 119
Affimed Therapeutics AG 120
Chipscreen Biosciences Ltd 121
Memgen, LLC. 122
Abiogen Pharma S.p.A. 123
Ascenta Therapeutics, Inc. 124
Semafore Pharmaceuticals, Inc. 125
ProNAi Therapeutics, Inc. 126
Yaupon Therapeutics, Inc. 127
Fate Therapeutics, Inc. 128
Xencor, Inc. 129
PharmaMar, S.A. 130
VentiRx Pharmaceuticals, Inc. 131
Biokine Therapeutics Ltd. 132
SymbioTec GmbH 133
TaiGen Biotechnology Co., Ltd. 134
Astellas Pharma GmbH 135
EpiZyme, Inc. 136
Non-Hodgkin Lymphoma Therapeutics Assessment 137
Assessment by Monotherapy Products 137
Assessment by Combination Products 138
Assessment by Route of Administration 139
Assessment by Molecule Type 141
Drug Profiles 144
StemEx - Drug Profile 144
MAbThera - Drug Profile 146
MAbThera - Drug Profile 149
MLN8237 - Drug Profile 151
Adcetris - Drug Profile 153
Adcetris - Drug Profile 156
PCI-32765 - Drug Profile 159
BiovaxID - Drug Profile 161
Chidamide - Drug Profile 163
Marqibo - Drug Profile 164
Forodesine - Drug Profile 167
Mechlorethamine Gel - Drug Profile 169
Folotyn - Drug Profile 170
CHOP-14 + Alemtuzumab - Drug Profile 173
Bendamustine + Rituximab - Drug Profile 175
Mitoxantrone + Chlorambucil + Dexamethasone - Drug Profile 176
Mitoxantrone + Dexamethasone + Fludarabine - Drug Profile 178
CMC-544 - Drug Profile 179
Inotuzumab Ozogamicin + Rituxan - Drug Profile 180
Revlimid - Drug Profile 182
RG7159 + Bendamustine - Drug Profile 184
Fludarabine + Total Body Irradiation + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 186
CHOP14 + G-CSF + MabCampath + Autologous Stem Cell Transplantation - Drug Profile 188
Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Mercaptopurine + Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile 190
CHEOP + Radiation Therapy - Drug Profile 193
Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Autologus Stem Cell Transplantation - Drug Profile 195
Fludarabine + Total Body Irradiation + Recipient Leukocyte Infusion + Nonmyeloablative Allogeneic Stem Cell Transplantation - Drug Profile 197
Total Body Irradiation + Recipient Leukocyte Infusion + Nonmyeloablative Allogeneic Stem Cell Transplantation - Drug Profile 199
Bexxar + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 201
Cyclophosphamide + Hydroxydaunorubicin + Vincristine + Prednisone + G-CSF + Alemtuzumab - Drug Profile 203
Lenalidomide - Drug Profile 205
BBR 2778 - Drug Profile 206
Umbilical Cord Blood Transplantation - Drug Profile 207
CHOP Regimen + Filgrastim + Cytarabine + Etoposide + Leucovorin Calcium + Melphalan + Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Hydrocortisone + Autologous Stem Cell Transplantation + Radiation Therapy - Drug Profile 209
Filgrastim + Rituximab + Sargramostim + CHOP Regimen + Carmustine + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Vincristine + Stem Cell Transplantation + Radiation Therapy - Drug Profile 211
Filgrastim + Rituximab + Sargramostim + CHOP Regimen + Carmustine + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Vincristine + Stem Cell Transplantation + Radiation Therapy - Drug Profile 214
Ifosfamide + Amsacrine + Etoposide - Drug Profile 217
Rituxan + CHOP Chemotherapy - Drug Profile 218
Cisplatin + Dexamethasone + Cytarabine + Rituximab + Autologus Stem Cell Transplantation - Drug Profile 220
Mega-CHOEP + Rituximab + Autologous Stem Cell Transplantation - Drug Profile 222
Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Leucovorin Calcium + Methotrexate + Therapeutic Hydrocortisone + Vinblastine - Drug Profile 224
Chlorambucil + Dexamethasone + Interferon Alfa - Drug Profile 228
R-CHOP14 + Darbepoetin Alfa - Drug Profile 230
Rituximab-HDS - Drug Profile 233
Cyclophosphamide + Doxorubicin + Vincristine + Prednisolone - Drug Profile 234
Mitoxantrone + Cyclophosphamide + Vincristine + Prednisolone - Drug Profile 236
Rituximab + Cyclophosphamide + Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate - Drug Profile 238
Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Filgrastim + Carboplatin + Etoposide + Ifosfamide - Drug Profile 240
Ibritumomab Tiuxetan - Drug Profile 243
Interferon Alfa-2b - Drug Profile 244
Rituximab - Drug Profile 245
Zolinza + Velcade - Drug Profile 246
Non-Hodgkin Lymphoma Therapeutics Drug Profile Updates 248
Non-Hodgkin Lymphoma Therapeutics Discontinued Products 284
Non-Hodgkin Lymphoma Therapeutics - Dormant Products 290
Non-Hodgkin Lymphoma Product Development Milestones 318
Featured News & Press Releases 318

Appendix 324
Methodology 324
Coverage 324
Secondary Research 324
Primary Research 324
Expert Panel Validation 324
Contact Us 325
Disclaimer 325

List of Table


Number of Products Under Development for Non-Hodgkin Lymphoma, H2 2012 17
Products under Development for Non-Hodgkin Lymphoma Comparative Analysis, H2 2012 18
Number of Products under Development by Companies, H2 2012 20
Number of Products under Development by Companies, H2 2012 (Contd..1) 21
Number of Products under Development by Companies, H2 2012 (Contd..2) 22
Number of Products under Development by Companies, H2 2012 (Contd..3) 23
Number of Products under Development by Companies, H2 2012 (Contd..4) 24
Number of Products under Development by Companies, H2 2012 (Contd..5) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 35
Comparative Analysis by Late Stage Development, H2 2012 36
Comparative Analysis by Mid Clinical Stage Development, H2 2012 37
Comparative Analysis by Early Clinical Stage Development, H2 2012 38
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 39
Products under Development by Companies, H2 2012 40
Products under Development by Companies, H2 2012 (Contd..1) 41
Products under Development by Companies, H2 2012 (Contd..2) 42
Products under Development by Companies, H2 2012 (Contd..3) 43
Products under Development by Companies, H2 2012 (Contd..4) 44
Products under Development by Companies, H2 2012 (Contd..5) 45
Products under Development by Companies, H2 2012 (Contd..6) 46
Products under Development by Companies, H2 2012 (Contd..7) 47
Products under Development by Companies, H2 2012 (Contd..8) 48
Products under Investigation by Universities/Institutes, H2 2012 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 68
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 69
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 70
Bristol-Myers Squibb Company, H2 2012 71
Johnson & Johnson, H2 2012 72
Boehringer Ingelheim GmbH, H2 2012 73
F. Hoffmann-La Roche Ltd., H2 2012 74
Kyowa Hakko Kirin Co., Ltd., H2 2012 75
Abbott Laboratories, H2 2012 76
Amgen Inc., H2 2012 77
Sanofi-Aventis, H2 2012 78
Eli Lilly and Company, H2 2012 79
Seattle Genetics, Inc., H2 2012 80
Genentech, Inc., H2 2012 81
Antigenics, Inc., H2 2012 82
Biotec Pharmacon ASA, H2 2012 83
Gilead Sciences, Inc., H2 2012 84
Merck & Co., Inc., H2 2012 85
Emergent BioSolutions Inc., H2 2012 86
Gamida Cell Ltd., H2 2012 87
Celltrion, Inc., H2 2012 88
ZIOPHARM Oncology, Inc., H2 2012 89
Millennium Pharmaceuticals, Inc., H2 2012 90
Novartis AG, H2 2012 91
Astellas Pharma Inc., H2 2012 92
Cephalon, Inc., H2 2012 93
Eisai Co., Ltd., H2 2012 94
Gedeon Richter Plc., H2 2012 95
Human Genome Sciences, Inc., H2 2012 96
ImmunoGen, Inc., H2 2012 97
Ono Pharmaceutical Co., Ltd., H2 2012 98
Pfizer Inc., H2 2012 99
Sigma-Tau S.p.A., H2 2012 100
SuperGen, Inc., H2 2012 101
Cell Therapeutics, Inc., H2 2012 102
Alfacell Corporation, H2 2012 103
Celgene Corporation, H2 2012 104
Incyte Corporation, H2 2012 105
Hana Biosciences, Inc., H2 2012 106
IMMUNOMEDICS, INC, H2 2012 107
Idera Pharmaceuticals, Inc., H2 2012 108
MethylGene Inc, H2 2012 109
NexMed, Inc., H2 2012 110
Northwest Biotherapeutics, Inc., H2 2012 111
Accentia Biopharmaceuticals, Inc., H2 2012 112
Allos Therapeutics, Inc, H2 2012 113
Cytokinetics, Inc, H2 2012 114
TopoTarget A/S, H2 2012 115
Mundipharma International Limited, H2 2012 116
Pharmacyclics, Inc., H2 2012 117
MorphoSys AG, H2 2012 118
Takara Bio Inc., H2 2012 119
Sareum Holdings plc, H2 2012 120
Innate Pharma SA, H2 2012 121
Transgene Biotek Ltd, H2 2012 122
Spectrum Pharmaceuticals, Inc., H2 2012 123
Affimed Therapeutics AG, H2 2012 124
Chipscreen Biosciences Ltd, H2 2012 125
Memgen, LLC., H2 2012 126
Abiogen Pharma S.p.A., H2 2012 127
Ascenta Therapeutics, Inc., H2 2012 128
Semafore Pharmaceuticals, Inc., H2 2012 129
ProNAi Therapeutics, Inc., H2 2012 130
Yaupon Therapeutics, Inc., H2 2012 131
Fate Therapeutics, Inc., H2 2012 132
Xencor, Inc., H2 2012 133
PharmaMar, S.A., H2 2012 134
VentiRx Pharmaceuticals, Inc., H2 2012 135
Biokine Therapeutics Ltd., H2 2012 136
SymbioTec GmbH, H2 2012 137
TaiGen Biotechnology Co., Ltd., H2 2012 138
Astellas Pharma GmbH, H2 2012 139
EpiZyme, Inc., H2 2012 140
Assessment by Monotherapy Products, H2 2012 141
Assessment by Combination Products, H2 2012 142
Assessment by Stage and Route of Administration, H2 2012 144
Assessment by Stage and Molecule Type, H2 2012 147
Non-Hodgkin Lymphoma Therapeutics Drug Profile Updates 252
Non-Hodgkin Lymphoma Therapeutics Discontinued Products 288
Non-Hodgkin Lymphoma Therapeutics Discontinued Products (Contd..1) 289
Non-Hodgkin Lymphoma Therapeutics Discontinued Products (Contd..2) 290
Non-Hodgkin Lymphoma Therapeutics Discontinued Products (Contd..3) 291
Non-Hodgkin Lymphoma Therapeutics Discontinued Products (Contd..4) 292
Non-Hodgkin Lymphoma Therapeutics Discontinued Products (Contd..5) 293
Non-Hodgkin Lymphoma Therapeutics Dormant Products 294
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..1) 295
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..2) 296
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..3) 297
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..4) 298
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..5) 299
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..6) 300
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..7) 301
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..8) 302
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..9) 303
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..10) 304
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..11) 305
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..12) 306
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..13) 307
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..14) 308
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..15) 309
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..16) 310
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..17) 311
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..18) 312
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..19) 313
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..20) 314
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..21) 315
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..22) 316
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..23) 317
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..24) 318
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..25) 319
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..26) 320
Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..27) 321

List of Chart


Number of Products under Development for Non-Hodgkin Lymphoma, H2 2012 17
Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 26
Late Stage Products, H2 2012 36
Mid Clinical Stage Products, H2 2012 37
Early Clinical Stage Products, H2 2012 38
Discovery and Pre-Clinical Stage Products, H2 2012 39
Assessment by Monotherapy Products, H2 2012 141
Assessment by Combination Products, H2 2012 142
Assessment by Route of Administration, H2 2012 143
Assessment by Stage and Route of Administration, H2 2012 144
Assessment by Molecule Type, H2 2012 145
Assessment by Stage and Molecule Type, H2 2012 146

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2500
$ 5000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top